Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | GMNN | O75496 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 5/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 5/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30555674 | 1.00 | EGFR (1.00) | EGFRERBB2MEN1MAPTMAPK1 | |
| SCHEMBL29766990 | 1.00 | EGFR (1.00) | EGFRERBB2MEN1MAPTMAPK1 | |
| SCHEMBL5909179 | 1.00 | EGFR (1.00) | EGFRERBB2MEN1MAPTMAPK1 | |
| SCHEMBL8996038 | 0.87 | EGFR (0.77) | EGFRERBB2MEN1MAPTMAPK1 | |
| SCHEMBL28558448 | 0.87 | EGFR (0.77) | EGFRERBB2MEN1MAPTMAPK1 | |
| SCHEMBL8996081 | 0.87 | EGFR (0.77) | EGFRERBB2MEN1MAPTMAPK1 | |
| SCHEMBL28558447 | 0.87 | EGFR (0.77) | EGFRERBB2MEN1MAPTMAPK1 | |
| SCHEMBL8996037 | 0.86 | EGFR (0.76) | EGFRERBB2MEN1MAPTMAPK1 | |
| SCHEMBL14354772 | 0.86 | EGFR (0.76) | EGFRERBB2MEN1MAPTMAPK1 | |
| SCHEMBL8995995 | 0.86 | EGFR (0.76) | EGFRERBB2MEN1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1156775-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2006-05-17 | — | — | EP | claimed |
| EP-1156775-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2001-11-28 | — | — | EP | claimed |
| US-6121269-A | TOPICALLY APPLYING A PROTEIN-TYROSINE KINASE INHIBITOR TO SKIN TO REDUCE ANDROGEN-STIMULATED HAIR GROWTH WITHOUT SIDE EFFECTS | GILLETTE COMPANY, THE, A DELAWARE CORPORATION | 2000-09-19 | — | — | US | claimed |
| WO-2000050002-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-08-31 | — | — | WO | claimed |
| WO-1991016892-A1 | STYRYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR PROTEIN TYROSINE KINASE | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-11-14 | — | — | WO | claimed |
| US-20250262213-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2025-08-21 | — | — | US | disclosed |
| US-12336995-B2 | Combination therapies | Mirati Therapeutics, Inc. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2025106901-A1 | COMBINATION CANCER THERAPIES WITH A KRAS MODULATOR AND AN RTK-MAPK PATHWAY INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025034919-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20240408099-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS | MIRATI THERAPEUTICS, INC | 2024-12-12 | — | — | US | disclosed |
| US-20220054491-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-02-24 | — | — | US | disclosed |
| US-10106818-B2 | Dual-color HIV reporter system for the detection of latently-infected cells | THE J. DAVID GLADSTONE INSTITUTES (US) | 2018-10-23 | — | — | US | disclosed |
| US-20060167026-A1 | Antipsychotic molecular-targeting epithelial growth factor receptor | HIROYUKI NAWA (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1156775-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2006-05-17 | — | — | EP | disclosed |
| US-RE38761-E1 | Styryl compounds which inhibit EGF receptor protein tyrosine kinase | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-07-19 | — | — | US | disclosed |
| EP-1156775-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6121269-A | TOPICALLY APPLYING A PROTEIN-TYROSINE KINASE INHIBITOR TO SKIN TO REDUCE ANDROGEN-STIMULATED HAIR GROWTH WITHOUT SIDE EFFECTS | GILLETTE COMPANY, THE, A DELAWARE CORPORATION | 2000-09-19 | — | — | US | disclosed |
| WO-2000050002-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-08-31 | — | — | WO | disclosed |
| US-5217999-A | Antigrowth agents | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1993-06-08 | — | — | US | disclosed |
| WO-1991016892-A1 | STYRYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR PROTEIN TYROSINE KINASE | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106818-B2 | Dual-color HIV reporter system for the detection of latently-infected cells | LUC7L2, PHAX, SRRT | EGFR 4019/4885ERBB2 4267/4885MEN1 4835/4885 |
| US-20240408099-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS | KRAS, NRAS, EGFR | EGFR 3/4885ERBB2 5/4885MEN1 415/4885 |
| US-20250262213-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | EGFR 4/4885ERBB2 5/4885MEN1 298/4885 |
| US-12336995-B2 | Combination therapies | KRAS, NRAS, HRAS | EGFR 4/4885ERBB2 5/4885MEN1 439/4885 |
| US-20220054491-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | EGFR 4/4885ERBB2 5/4885MEN1 439/4885 |
| US-20060167026-A1 | Antipsychotic molecular-targeting epithelial growth factor receptor | EGFR, BDNF, NTRK2 | EGFR 1/4885ERBB2 7/4885MEN1 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.